Building on the pioneering work of RXi's Scientific Advisory Board Chairman and Nobel Laureate Dr. Craig Mello, Scientists at RXi have used an alternative approach to delivery, where drug-like as well as delivery properties are built into the RNAi compound itself. sd-rxRNA compounds are novel RNAi compounds with enhanced properties for therapeutic use. RXI-109, an sd-rxRNA compound, is initially being developed to reduce or inhibit scar formation in the skin and in the eye. RXI-109 is currently being evaluated in Phase 2a clinical trials in dermatology and a Phase 1/2 trial in ophthalmology.
